Patient-reported outcomes supporting anticancer product approvals

Journal of Clinical Oncology

Volumn 25, Issue 32, 2007, Pages 5094-5099

  Rock, Edwin P ^a   Kennedy, Dianne L ^a   Furness, Melissa H ^a   Pierce, William F ^a   Pazdur, Richard ^a   Burke, Laurie B ^a  

^a CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; AMIFOSTINE; ANALGESIC AGENT; CISPLATIN; CYCLOPHOSPHAMIDE; CYTARABINE; DOXORUBICIN; ETOPOSIDE; FLUOROURACIL; GEMCITABINE; HYDROCORTISONE; IMATINIB; MITOXANTRONE; PALIFERMIN; PHOTOFRIN; PLACEBO; PREDNISONE; TOPOTECAN; VINCRISTINE;

ACUTE GRANULOCYTIC LEUKEMIA; ANOREXIA; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER RISK; CANCER STAGING; CANCER SURVIVAL; CHRONIC MYELOID LEUKEMIA; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONFERENCE PAPER; CONTROLLED STUDY; COUGHING; DRUG APPROVAL; DRUG EFFICACY; DRUG MEGADOSE; DYSPNEA; ESOPHAGUS CANCER; FATIGUE; FOLLOW UP; FOOD AND DRUG ADMINISTRATION; HEAD AND NECK CANCER; HEMOPTYSIS; HOARSENESS; HODGKIN DISEASE; HUMAN; INSOMNIA; LOW DRUG DOSE; LUNG NON SMALL CELL CANCER; LUNG SMALL CELL CANCER; LYMPHATIC LEUKEMIA; MONOTHERAPY; MUCOSA INFLAMMATION; MULTIPLE MYELOMA; NONHODGKIN LYMPHOMA; PAIN; PANCREAS CANCER; PRIORITY JOURNAL; PROSTATE CANCER; QUALITY OF LIFE; THORAX PAIN; TREATMENT OUTCOME; TREATMENT RESPONSE; TUMOR GROWTH; XEROSTOMIA;

ANTINEOPLASTIC AGENTS; CLINICAL TRIALS AS TOPIC; DRUG APPROVAL; HUMANS; NEOPLASMS; PATIENT SATISFACTION; QUALITY INDICATORS, HEALTH CARE; QUALITY OF LIFE; SICKNESS IMPACT PROFILE; TREATMENT OUTCOME; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 36849059118     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2007.11.3803     Document Type: Conference Paper

References (15)

1. US Food and Drug Administration: Guidance for Industry. Patient-reported outcome measures: Use in medical product development to support labeling claims. http://www.fda.gov/cder/guidance/5460dft.pdf
2. US Food and Drug Administration: Draft FDA Guidance for Industry: Clinical trial end points for the approval of cancer drugs and biologics. http://www.fda.gov/cder/guidance/6592dft.pdf
3. Johnson JR, Williams G, Pazdur R: End points and United States Food and Drug Administration approval of oncology drugs. J Clin Oncol 21:1404-1411, 2003
4. Johnson JR, Temple R: Food and Drug Administration requirements for approval of new anticancer drugs. Cancer Treat Rep 69:1155-1159, 1985
5. O'Shaughnessy JA, Wittes RE, Burke G, et al: Commentary concerning demonstration of safety and efficacy of investigational anticancer agents in clinical trials. J Clin Oncol 9:2225-2232, 1991
6. US Food and Drug Administration: Photofrin product label. http://www.fda.gov/cder/foi/label/2003/20451s012_photofrin_lbl.pdf
7. US Food and Drug Administration: Gemzar product label. http://www.fda.gov/cder/foi/label/2005/020509s033lbl.pdf
8. US Food and Drug Administration: Novantrone product label. http://www.fda.gov/cder/foi/nda/2000/21120.pdf_Novantrone_Prntlbl.pdf
9. US Food and Drug Administration: Hycamtin product label. http://www.fda.gov/cder/foi/label/2006/020671s014lbl.pdf
10. US Food and Drug Administration: Ethyol product label. http://www.fda.gov/cder/foi/label/2003/20221slr017_ethyol_lbl.pdf
11. US Food and Drug Administration: Gleevec product label. http://www.fda.gov/cder/foi/label/2006/021588s009lbl.pdf
12. Cohen MH, Williams G, Johnson JR, et al: Approval summary for imatinib mesylate capsules in the treatment of chronic myelogenous leukemia. Clin Cancer Res 8:935-942, 2002
13. Pazdur R: U.S. Food and Drug Administration Drug Approval Summary.Cohen MH, Johnson JR, Conversion of imatinib mesylate (STI571; Gleevec) tablets from accelerated approval to full approval. Clin Cancer Res 11:12-19, 2005
14. US Food and Drug Administration: Kepivance product label. http://www.fda.gov/cder/foi/label/2005/125103s0010lbl.pdf
15. Rock EP, Scott JA, Kennedy DL, et al: Challenges to use of health-related quality-of-life for FDA approval of anticancer products. J Natl Cancer Inst (in press)